Aurinia Pharmaceuticals (AUPH) to Release Quarterly Earnings on Monday

Key Points

• Upcoming Q1 results on May 11: Aurinia will likely report Q1 2026 earnings before the market opens on Monday, May 11, with analysts forecasting EPS of $0.18 and revenue of about $76.98 million; the earnings call is scheduled for 8:30 AM ET.
• Big prior quarter beat: In its last report Aurinia posted EPS of $1.53 versus the $0.21 consensus and revenue of $77.11 million, and analysts now expect roughly $1.00 EPS for the current and next fiscal years.
• Insider buying and market view: Director Kevin Tang bought 516,439 shares (~$7.22M), raising his stake to 11.85M shares, while the stock trades around $15.65 (market cap ~$2.03B) with a consensus rating of "Moderate Buy" and a $17.25 price target.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP will likely be announcing its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of $0.18 per share and revenue of $76.9790 million for the quarter. Investors may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Monday, May 11, 2026 at 8:30 AM ET.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $1.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $1.32. Aurinia Pharmaceuticals had a return on equity of 27.47% and a net margin of 101.46%.The company had revenue of $77.11 million for the quarter, compared to analysts' expectations of $74.70 million. On average, analysts expect Aurinia Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Aurinia Pharmaceuticals Trading Up 2.0%

NASDAQ:AUPH traded up $0.30 during midday trading on Monday, hitting $15.65. The stock had a trading volume of 352,499 shares, compared to its average volume of 1,062,523. Aurinia Pharmaceuticals has a one year low of $7.28 and a one year high of $16.88. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of 7.53 and a beta of 1.44. The stock has a 50-day moving average of $15.05 and a 200 day moving average of $14.87. The company has a quick ratio of 4.76, a current ratio of 5.25 and a debt-to-equity ratio of 0.09.

Insider Transactions at Aurinia Pharmaceuticals

In related news, Director Kevin Tang bought 516,439 shares of the company's stock in a transaction on Friday, February 27th. The shares were acquired at an average price of $13.99 per share, with a total value of $7,224,981.61. Following the transaction, the director owned 11,845,939 shares of the company's stock, valued at $165,724,686.61. The trade was a 4.56% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 12.20% of the company's stock.

Institutional Trading of Aurinia Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership boosted its position in Aurinia Pharmaceuticals by 0.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,387,194 shares of the biotechnology company's stock valued at $54,026,000 after acquiring an additional 13,173 shares in the last quarter. Renaissance Technologies LLC boosted its position in Aurinia Pharmaceuticals by 9.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,590,135 shares of the biotechnology company's stock valued at $25,363,000 after acquiring an additional 140,535 shares in the last quarter. Marshall Wace LLP boosted its position in Aurinia Pharmaceuticals by 6.2% during the 4th quarter. Marshall Wace LLP now owns 1,574,957 shares of the biotechnology company's stock valued at $25,121,000 after acquiring an additional 91,825 shares in the last quarter. Geode Capital Management LLC boosted its position in Aurinia Pharmaceuticals by 1.5% during the 4th quarter. Geode Capital Management LLC now owns 1,507,869 shares of the biotechnology company's stock valued at $24,047,000 after acquiring an additional 22,169 shares in the last quarter. Finally, Two Sigma Investments LP boosted its position in Aurinia Pharmaceuticals by 728.6% during the 3rd quarter. Two Sigma Investments LP now owns 1,341,067 shares of the biotechnology company's stock valued at $14,819,000 after acquiring an additional 1,179,219 shares in the last quarter. Institutional investors own 36.83% of the company's stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Aurinia Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Friday. Three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $17.25.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company's proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company's lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.